2023
Onconephrology: Core Curriculum 2023
Yarandi N, Shirali A. Onconephrology: Core Curriculum 2023. American Journal Of Kidney Diseases 2023, 82: 743-761. PMID: 37855786, DOI: 10.1053/j.ajkd.2023.04.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseChimeric antigen receptor T cellsAntigen receptor T cellsAJKD's Core CurriculumAcute kidney injuryKidney transplant recipientsChronic kidney diseaseReceptor T cellsKidney injuryTransplant recipientsElectrolyte disordersCell transplantClinical syndromeMonoclonal gammopathyGlomerular diseaseT cellsCancer riskClinical decisionCancer treatmentDiseaseOnconephrologySyndromeCancerSpecific considerationsHypertensionOnco-Nephrology Kidney Disease in the Cancer Patient
Yarandi N, Shirali A. Onco-Nephrology Kidney Disease in the Cancer Patient. Medical Clinics Of North America 2023, 107: 749-762. PMID: 37258012, DOI: 10.1016/j.mcna.2023.03.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseAcute kidney injuryChronic kidney diseaseDifferent clinical manifestationsSubspecialty of nephrologyOnco-NephrologyKidney injuryElectrolyte disturbancesClinical manifestationsCancer patientsGeneral internistsPatientsDiseaseCancerHypertensionProteinuriaInternistsInjuryNephrology
2022
Cancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancy
2019
High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?
Kitchlu A, Shirali A. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best? Journal Of Onco-Nephrology 2019, 3: 11-18. DOI: 10.1177/2399369319827305.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
35 Kidney Disease Caused by Therapeutic Agents
Perazella M, Shirali A. 35 Kidney Disease Caused by Therapeutic Agents. 2018, 334-344. DOI: 10.1016/b978-0-323-47794-9.00035-4.BooksKidney diseaseTherapeutic agentsDrug-induced renal toxicityProteinuria/nephrotic syndromeFrequent adverse consequencesChronic kidney diseaseChronic kidney injuryDrugs of abuseSubgroup of individualsDrug nephrotoxicityKidney injuryMost medicationsNephrotoxic drugsTubular dysfunctionNephrotic syndromeRenal toxicityDrug therapyRisk factorsTherapeutic medicationsRenal syndromeAppropriate careMedicationsNephrotoxicitySyndromeAdverse consequences